D. Lynn Kirkpatrick
Founder of Phusis Therapeutics, Inc. and ProlX Pharmaceuticals Corp., D. Lynn Kirkpatrick currently is President, Chief Executive Officer & Director at Ensysce Biosciences, Inc. and President, Chief Executive Officer & Director at Ensysce Biosciences, Inc.
In her past career Dr. Kirkpatrick occupied the position of President & Chief Executive Officer at ProlX Pharmaceuticals Corp., Chief Scientific Officer of Biomira, Inc., Chief Scientific Officer at Cascadian Therapeutics, Inc. and Professor at the University of Regina.
Dr. Kirkpatrick received a doctorate and an undergraduate degree from the University of Saskatchewan.
Transactions
Date
Transaction
Value
| 06/30/2021 | 284,851 | Award at $0 per share. | 0 |
